Drug Profile
exoSTING
Alternative Names: CDK 002Latest Information Update: 17 Feb 2023
Price :
$50
*
At a glance
- Originator Codiak BioSciences
- Class Antineoplastics; Exosome therapies; Immunotherapies; Small molecules
- Mechanism of Action MPYS protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Preclinical Meningeal carcinomatosis
- Discontinued Glioblastoma
Most Recent Events
- 23 Dec 2022 Codiak BioSciences completes a phase I/II trial in advanced Solid Tumor in the USA and United kingdom (NCT04592484)
- 11 Aug 2022 9364946- KDM, FET updated
- 30 Jun 2022 Updated safety, pharmacokinetic and pharmacodynamic data from a phase I/II trial in Solid tumours released by Codaik BioSciences